.png){kind=icon}
.png){kind=icon}
Return
Successful treatment with erlotinib plus ramucirumab in a patient with non-small-cell lung cancer harboring EGFR exon 20 insertion mutation
.png){kind=icon}
PRE
AI
K
K
Y
Y
DOI：10.1097/CAD.0000000000001777.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
As epidermal growth factor receptor (EGFR) exon 20 insertion mutations generally result in poor sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), the administration of EGFR-TKIs is not recommended in non-small-cell lung cancer (NSCLC). Nonetheless, EGFR exon 20 A763_Y763insFQEA, a genotype of EGFR exon 20 insertion mutations, has some sensitivity to EGFR-TKIs. However, the therapeutic effects of EGFR-TKIs alone for EGFR exon 20 A763_Y763insFQEA are insufficient compared to those for common EGFR mutations. Therefore, more effective treatment options are required for this mutation. Herein, we present a case in which treatment with erlotinib plus ramucirumab led to a complete response and progression-free survival of 13 months in a 79-year-old man with advanced NSCLC harboring EGFR exon 20 A763_Y763insFQEA. This case suggests that this regimen should be considered as an effective treatment option for such patients.
Keywords:
A763_Y763insFQEA
epidermal growth factor receptor
erlotinib
exon 20 insertion
ramucirumab
tyrosine kinase inhibitor
Journal
A
IF:
2.2
Papers:
50
Citations:
4.2K
Organization
Cited Papers